Abstract: An aqueous ophthalmic composition comprising loteprednol etabonate, and polyacryclic acid. The composition has a viscosity in the range from about 300 cp to about 1500 cp, and a total concentration of cations of less than about 50 mM. The ophthalmic composition is used to treat patients suffering from allergic conjunctivitis, and includes instructing a person suffering from ocular itching resulting from allergic conjunctivitis to administer once or twice daily in the form of one or more eye drops the aqueous ophthalmic composition described.

Abstract: An aqueous ophthalmic composition comprises a carboxy-containing polyanionic polymer that has a viscosity in the range from about 300 cp to about 1500 cp outside the eye and a total concentration of cations of less than about 50 mM, wherein the viscosity of the composition does not increase when the composition comes into contact with surface ocular fluid.

Abstract: The use of compositions containing one or more ether amine antimicrobial agents and/or ether amine derivative antimicrobial agents in an amount effective to disinfect and/or preserve medical devices is described. Solutions containing one or more ether amine antimicrobial agent- and/or ether amine derivative antimicrobial agent-containing compositions and methods of making and using the same are also described.

Abstract: Disclosed in embodiments are gel formulations which are not subject to the settling out phenomena that may be observed with Loteprednol etabonate suspensions.

Abstract: The use of compositions containing one or more ether amine antimicrobial agents and/or ether amine derivative antimicrobial agents in an amount effective to disinfect and/or preserve medical devices is described. Solutions containing one or more ether amine antimicrobial agent- and/or ether amine derivative antimicrobial agent-containing compositions and methods of making and using the same are also described.

Abstract: The invention provides a method for inhibiting the binding of a biguanide disinfectant in aqueous solution to a poly(ethylene) solid in contact with said solution comprising providing in said solution an amount of cyclodextrin sufficient to inhibit binding of the biguanide disinfectant to the poly(ethylene) solid.

Abstract: The present invention provides an optically clear, hydrophilic coating upon the surface of a non-plasma treated hydrophobic hydrogel lens by heating the lens in an aqueous solution containing a surface-protective agent. Alternately, the non-plasma treated hydrophobic hydrogel lens may be subjected to ultrasonication while immersed in an aqueous solution containing a surface-protective agent.

Abstract: The present invention provides an optically clear, hydrophilic coating upon the surface of a silicone hydrogel lens by plasma treating the lens and subsequently heating the lens in an aqueous solution containing a surface-protective agent.

Abstract: The present invention is directed to a method of treating dry eye by instilling eyedrops of a composition containing a cationic cellulosic polymer. Such compositions have been found to alleviate the symptoms of dry eye without requiring the presence of anionic therapeutic agents. Low ionic strength solutions are particularly preferred.

Abstract: The present invention provides methods and compositions for cleaning and disinfecting contact lenses, which compositions comprise a carbonate or bicarbonate salt, a non-carbonate buffer system, an antimicrobial agent, and a non-ionic surfactant. Products according to the present invention, especially multi-purpose solutions, provide simultaneous disinfection and cleaning of contact lenses including the prevention or removal of protein and lipid deposits and other debris.

Abstract: The present invention is directed to an ophthalmic solution for the treatment of contact lenses while worn in the eye. In particular, the composition contains ethoxylated glucose derivative, tyloxapol, and a polyoxyethylene-polyoxypropylene nonionic surfactant. The ophthalmic solution containing such a combination of components can be applied, in the form of drops, to the eye or to contact lens in the eye. In one embodiment of the invention, the composition is used for reducing unwanted lipid or protein deposition on extended-wear lenses, including lenses made from relatively hydrophobic materials such as silicon hydrogels.

Abstract: There are disclosed ophthalmic compositions having high water-binding properties which are useful as: moisturizing and lubricating (i.e. artificial tear) solutions, dry eye therapies, contact lens wetting and lubricating solutions, and as delivery vehicles for ophthalmic drugs. The subject compositions include glycerin in combination with propylene glycol. The subject compositions may further include cellulose derivatives, e.g. hydroxypropyl methyl cellulose, along with preservatives, e.g. benzylalkonium chloride, PHMB, sorbic acid, etc. Preferred compositions have at least 11% bound water, a pH from about 7.1 to 7.5, and an osmolality between about 280 to about 320 mOsm/Kg.

Abstract: A chewable cold/sinus preparation comprising a bitter tasting mixture of a decongestant such as pseudoephedrine and an antihistamine such as diphenhydramine and/or chlorpheniramine maleate is made with no bitter, metallic taste or unpleasant mouthfeel by adsorbing the active drug mixture using a wet granulation process onto a silicon dioxide carrier which comprises from about 50 to about 85% of total weight of the adsorbate composition. A truly multi-symptom relief formula is prepared through the optional addition of an antitussive such as dextromethorphan hydrobromide and/or an analgesic such as meclofenamic acid, aspirin or ibuprofen. Additional excipients such as flavors, sweeteners, lubricants and bulk fillers are added for better taste, improved mouthfeel and as an aid to the tabletting process.

Abstract: A method for coating pharmaceutical tablets is disclosed in which polymeric coating ingredients are combined with saccharides in a melt spinning operation to form composite particulates. The particulates are then dispersed in water to form an aqueous polymer coating solution, followed by application to pharmaceutical tablets by such methods as spray coating. The particulates dissolve extremely rapidly in water to form a dispersion of the polymer coating ingredients. Such rapid dissolution allows for increased processing rates and avoids disadvantages of the prior art such as the requirement of high shear rate mixing for long times.

Abstract: A method for coating pharmaceutical tablets is disclosed in which polymeric coating ingredients are combined with saccharides in a melt spinning operation to form composite particulates. The particulates are then dispersed in water to form an aqueous polymer coating solution, followed by application to pharmaceutical tablets by such methods as spray coating. The particulates dissolve extremely rapidly in water to form a dispersion of the polymer coating ingredients. Such rapid dissolution allows for increased processing rates and avoids disadvantages of the prior art such as the requirement of high sheer rate mixing for long times.

Abstract: Powdered psyllium seek husks are rendered rapidly and uniformly dispersible in water by admixing a solvent selected from the group consisting of benzyl alcohol, propylene glycol, triacetin and mixtures thereof with powdered psyllium seed husks.

Abstract: A medicament adsorbate of analgesics and process for making same. The medicament adsorbate comprises a complex magnesium aluminum silicate having sorbed therein an analgesic. The complex magnesium aluminum silicate has the following typical chemical analysis:______________________________________ Ratio to Percent by Weight Aluminum Oxide ______________________________________ Silicon dioxide 56 to 59 14.0 to 29.5 Magnesium oxide 21 to 24 5.2 to 12.0 Aluminum oxide 2.0 to 4.0 1 Ferric oxide 0.4 to 0.6 Calcium oxide 1.1 to 1.5 Sodium oxide 2.5 to 3.5 Potassium oxide 0.5 to 1.0 Ignition Loss 5.5 to 12.

Abstract: A medicament adsorbate of antiasthmatics and process for making same. The medicament adsorbate comprises a complex magnesium aluminum silicate having sorbed therein an antiasthmatic. The complex magnesium aluminum silicate has the following typical chemical analysis:______________________________________ Ratio to Percent by Weight Aluminum Oxide ______________________________________ Silicon dioxide 56 to 59 14.0 to 29.5 Magnesium oxide 21 to 24 5.2 to 12.0 Aluminum oxide 2.0 to 4.0 1 Ferric oxide 0.4 to 0.6 Calcium oxide 1.1 to 1.5 Sodium oxide 2.5 to 3.5 Potassium oxide 0.5 to 1.0 Ignition Loss 5.5 to 12.

Abstract: A medicament adsorbate of decongestants and process for making same. The medicament adsorbate comprises a complex magnesium aluminum silicate having sorbed therein a decongestant. The complex magnesium aluminum silicate has the following typical chemical analysis:______________________________________ Ratio to Percent by Weight Aluminum Oxide ______________________________________ Silicon dioxide 56 to 59 14.0 to 29.5 Magnesium oxide 21 to 24 5.2 to 12.0 Aluminum oxide 2.0 to 4.0 1 Ferric oxide 0.4 to 0.6 Calcium oxide 1.1 to 1.5 Sodium oxide 2.5 to 3.5 Potassium oxide 0.5 to 1.0 Ignition Loss 5.5 to 12.

Abstract: A process for preparing a medicament adsorbate by sorbing a medicament drug onto a swollen hydrated complex magnesium aluminum silicate and drying the swollen mass to a final solvent content of up to about 20% by weight of the medicament adsorbate.